Warrenton

This research focuses on people with geographic atrophy caused by age-related macular degeneration (AMD). AMD damages the macula, the light-sensitive part of the retina, leading to worsening central vision. Geographic atrophy is an advanced form where retinal cells waste away, potentially causing permanent vision loss. The study observes how patients with this condition are treated in regular medical practice, especially those receiving avacincaptad pegol, a US-approved treatment for geographic atrophy. Participants in this observational study have already decided with their doctors to begin treatment with avacincaptad pegol via intravitreal injection. The study does not assign treatment but collects information on how this drug is used, monitoring patients over time. This includes tracking treatment patterns, safety, and any medical problems linked to avacincaptad pegol. The study runs for about five years, recording ongoing care and treatment decisions. During the study, participants will have routine eye exams and complete surveys about their eye health. Surveys occur at treatment start, every six months for two years, then annually. Researchers will gather data from medical records on the number and frequency of injections, treatment duration, reasons for stopping treatment, and patient characteristics. They will also monitor vision changes and adverse events. This long-term follow-up helps understand real-world use and safety of avacincaptad pegol in geographic atrophy care.

Researchers are conducting a phase 3 randomized, double-masked study to compare the effectiveness of EYP-1901, a tyrosine kinase inhibitor, against Aflibercept in patients with diabetic macular edema (DME). The study focuses on evaluating changes in best corrected visual acuity and injection burden over a one-year period. This trial is sponsored by EyePoint Pharmaceuticals, Inc. and aims to provide more treatment options for this eye condition. Participants will receive either EYP-1901 (2686 µg) or Aflibercept (2 mg) through intravitreal injections directly into the eye. The study is designed with parallel groups and uses random assignment to one of the two treatments. Both treatments will be administered under quadruple masking to maintain unbiased results. The main treatment period lasts for 56 weeks with monitoring of visual acuity and injection frequency. During the trial, participants will undergo assessments including measuring best corrected visual acuity (BCVA) at weeks 52 and 56 to evaluate changes. Researchers will also track the rate of injections to understand the treatment burden. Participants will be monitored regularly to ensure safety and adherence. The total participation time spans over one year, with scheduled visits for evaluations, injections, and safety checks.